5:42 PM · 24 February 2022

Moderna stock surges after upbeat quarterly results

Moderna (MRNA.US) stock rose over 10% during today's session after the vaccine maker reported solid quarterly results. 

  • The biotech company earned an adjusted $11.29 per share on $7.2 billion of revenue, easily beating market expectations of  $9.90 in earnings per share on $6.78 billion of revenue. 
  • The company’s CEO told CNBC that he thought people would need another Covid booster shot in the fall.
  • Modeerna expects at least $19 billion ofcoronavirus vaccine - Spikevax sales in 2022, with additional signed options of approximately $3 billion.
  • Company unveiled a new $3 billion share repurchase plan.

Moderna (MRNA.US) stock fell sharply in recent months, however it seems that buyers managed to halt declines around $149.60 level which coincides with 78.6% Fibonacci retracement of the upward wave launched at the beginning of 2020 and 50 SMA (green line). As long as the price sits above this level, upward move may be resumed. On the other hand, if sellers manage to regain control, then another downward impulse towards support at $56.55 may be launched. Source: xStation5

6 November 2026, 7:12 PM

Daily summary: Wall Street rebounds after the sell-off 🔼 US dollar strengthens on solid NFP data, oil prices fall

6 November 2026, 7:00 PM

Vistra shares surge nearly 10% after earnings, driven by strong AI power demand

6 November 2026, 3:27 PM

US Open: Nasdaq rebounds after the largest decline since 19-month 🔼 Lam Research surges 12%

6 November 2026, 11:53 AM

Airbnb surges 12% driven by revenue dynamic at 3-year high

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits